COLLECTION SPONSORS
We are grateful for the support of our Sponsors Merck and Alnylam. As always, Nature carries sole responsibility for all editorial content.
Top of pageProduced with support from: Merck and Alnylam
RNA interference (RNAi) represents one of the most promising and rapidly advancing technologies in biology and drug discovery today. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, may be on the horizon. RNAi therapeutics target the 'root' genetic cause of diseases by potently silencing specific messenger RNA, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a brand new way.
Merck and Alnylam are committed to being at the forefront of the discovery and advancement of RNAi therapeutics. For more than a century, Merck has been committed to developing novel medicines for human health, and that commitment continues today, exemplified through collaborations with innovative companies like Alnylam in the development of RNAi therapeutics.
Alnylam was founded by cutting-edge scientists and pioneers in the discovery of RNAi. Alnylam's mission is to build a leading product company founded on RNAi. By attracting top scientists in the field and compiling the industry's strongest intellectual property portfolio, Alnylam has created a strong foundation for the successful development of a robust pipeline of RNAi therapeutics for a wide range of human diseases.
RNAi has an important role in future drug development - that is why we have worked together to sponsor this Nature collection.
Visit www.merck.com and www.merckresearchlaboratories-boston.com to learn more about Merck and our new state-of-the-art Boston research laboratory.
Visit www.alnylam.com to learn more about Alnylam.
